This page shows the latest Onbrez news and features for those working in and with pharma, biotech and healthcare.
The inhaler is currently used as part of Novartis' Ultibro Breezhaler, Onbrez Breezhaler and Seebri Breezhaler COPD treatments.
Novartis plans a 2019 launch for the new device, which will be available for its COPD portfolio of Onbrez, Breezhaler Seebri, and Ultibro Breezhaler.
and Onbrez, respectively.
The product, which is to be marketed as Xoterna Breezhaler in some countries, combines indacaterol - a long-acting beta-adrenergic agonist (LABA) present in Novartis' Onbrez - and glycopyrronium bromide - a
The companies have called time on their partnership, which covered Novartis' Onbrez, Seebri and QVA149, just over a year after it was signed. ... Novartis will now go it alone in promoting Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and
Seebri (glycopyrronium bromide) has been approved as a once-daily inhaled treatment for adults with COPD, and will join Novartis' long-acting beta agonist Onbrez/Arcapta (indacaterol maleate) which is already ... Both Seebri and Onbrez are expected to
More from news
Approximately 1 fully matching, plus 14 partially matching documents found.
Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...